Single or Triple Uterine Tourniquet at Myomectomy

Sponsor
Ragıp Atakan Al (Other)
Overall Status
Completed
CT.gov ID
NCT02392585
Collaborator
(none)
60
1
2
26
2.3

Study Details

Study Description

Brief Summary

The aim of study is to compare triple tourniquet vs. single tourniquet to reduce blood loss at open myomectomy.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Single tourniquet
  • Procedure: Triple tourniquet
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Triple Tourniquet vs. Single Tourniquet to Reduce Haemorrhage During Myomectomy: a Prospective Randomised Controlled Trial
Study Start Date :
Mar 1, 2015
Actual Primary Completion Date :
Mar 1, 2016
Actual Study Completion Date :
May 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Single tourniquet

Procedure: Single tourniquet
Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.

Active Comparator: Triple tourniquet

Procedure: Triple tourniquet
Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os. Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary.

Outcome Measures

Primary Outcome Measures

  1. Estimated blood loss at the end of myomectomy [15 minutes postoperatively]

    Surgical blood loss will be estimated by sum of the volume of suction fluid and blood loss quantitated by gravimetric method. Suction fluid will be measured at the end of operation and volume of irrigation fluid will be subtracted from total suction volume. ◦Surgical drapes, sponges and towels will be weighted before and just after surgery. The blood loss will be estimated as differences in gram by weighing when 1ml blood supposed as 1.06 gr.

Secondary Outcome Measures

  1. The amount of transfusions [7 Days]

    Erythrocyte transfusions will be allowed when haemoglobin dropped below 8 g/dL.

  2. A change in hemoglobin [At baseline and 48 hours after surgery]

  3. Volume in drains [7 days]

    Drain will be removed when discharge drops below 50 ml/day

  4. Peri-operative complications [6 weeks]

    Including but not limited to fever, pelvic infections, wound infections.

  5. Total operation time [5 minutes post operatively]

    Skin to skin operation time

  6. Tourniquet time [5 minutes after tourniquet removed]

Other Outcome Measures

  1. Anti-Mullerian Hormone levels variation [One year postoperatively]

    Anti-Mullerian Hormone levels before surgery, 6 months and 12 months after surgery

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 48 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Three or more uterine myoma

  2. At least one myoma ≥ 8 cm, if there is less than three myoma

Exclusion Criteria:
  1. Pedunculated myoma,

  2. broad ligament myoma

Contacts and Locations

Locations

Site City State Country Postal Code
1 Atatürk Üniversitesi Araştırma Hastanesi Erzurum Turkey 25240

Sponsors and Collaborators

  • Ragıp Atakan Al

Investigators

  • Principal Investigator: Neset Gümüsburun, MD, Ataturk University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ragıp Atakan Al, Assoc.Prof, Ataturk University
ClinicalTrials.gov Identifier:
NCT02392585
Other Study ID Numbers:
  • ATAUNİ23
First Posted:
Mar 19, 2015
Last Update Posted:
Feb 12, 2019
Last Verified:
Feb 1, 2019
Keywords provided by Ragıp Atakan Al, Assoc.Prof, Ataturk University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 12, 2019